Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Conventional chemotherapy can wreak havoc on healthy tissue, causing painful side effects, and it’s not always effective. Nanotechnology-based methods to deliver these drugs only to cancerous cells have shown promise, but they don’t work for all cancers. Now a handful of research groups are developing more-complex approaches that use microscopic carriers to deliver a variety of particles–including drugs, molecular tags that target tumors, and imaging agents to monitor and destroy cancer cells. In theory, these microscopic delivery vehicles would evade the body’s defenses and target blood vessels near a tumor, then release their payload.

While the technology is still in its early stages, researchers at the University of Texas in Houston have taken a first step by engineering tiny discs of porous silicon that can be used to deliver two types of nanoparticles simultaneously. Mauro Ferrari, a professor of biomedical engineering, fabricated porous silicon using previously developed methods and then used photolithography to carve out tiny structures shaped like red blood cells, but about half the size. (Computer models suggest that the structures will tend to hug the inside of blood vessel walls, a crucial property for targeted delivery.)

Ferrari and collaborators then loaded the pores with quantum dots and carbon nanotubes. When administered to cells growing in a dish, the silicon carriers begin to break down, releasing their cargo over the course of several hours. The cells then absorbed the nanoparticles, which accumulated in distinct areas inside the cells. The work was published last month in the journal Nature Nanotechnology.

Ferrari’s approach, and others like it, might overcome some of the drawbacks of current nanotechnology-based drug delivery. In one current technology, hollow, nanoscopic containers called liposomes or micelles are loaded with a drug and injected into the bloodstream. Since the blood vessels that feed tumors tend to be leaky, these nanoparticles tend to accumulate more in tumors than in other tissue. The approach has been approved for use in treating breast cancer and ovarian cancer. But not all tumors have leaky vasculature, Ferrari says, limiting the applications of this approach. His system, on the other hand, can be targeted to cancer cells using antibodies and other targeting molecules, eliminating the need to rely on leaky blood vessels.

Others are already trying a similar approach–using targeting molecules attached to nanoparticles–and, in some cases, are about to begin clinical trials. But unlike liposomes, which can carry significant drug payloads, these nanoparticles only carry a relatively small amount of drug on their surface. What’s more, many of the particles can be trapped or destroyed by the body’s defenses, making it difficult to deliver an effective dose. In Ferrari’s approach, the microscopic silicon carrier would protect the nanoparticles and deliver them in large numbers to the vicinity of the tumor, increasing the chances that the drugs will reach the cancer cells in large amounts.

0 comments about this story. Start the discussion »

Credit: Rita Serda / Matthew Landry – The University of Texas Health Science Center at Houston.

Tagged: Biomedicine, cancer, nanotechnology, imaging, drugs, nanomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me